🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Read the recent @IMI_JU article on PERSIST-SEQ here: imi.europa.eu/news-events/ne…

PERSIST-SEQ's Principal Investigator Alexander van Oudenaarden (Director of Hubrecht Institute, Professor at Utrecht University and Principal Investigator at Oncode Institute) explains the research in this @IMI_JU-funded project, our ambitions and anticipated milestones. Read the MedNet interview below:

📢There are two open positions to join our lab 🥼 🧪 🧫. Please RT ➡️ Bioinformatician PERSIST-SEQ bit.ly/3r0UIrC ➡️mach3cancer.org Advanced Digital Microscopy & Organoids bit.ly/3tUTfVU More details 👇🏼👇🏼👇🏼

📢We are hiring #Postdoctoral Fellow/ Research Officer to participate in #data analysis, methodology development & hypothesis generation within the #PersistSeq consortium. ➡️bit.ly/3r0UIrC #IRBJobs #DataScience #postdocjobs

Now available: PERSIST-SEQ brochure! Find out more about the research in the Innovative Health Initiative-funded PERSIST-SEQ project, our expected impact, strategy and the consortium here: persist-seq.org/our-research/p… Oncode Institute AstraZeneca Single Cell Discoveries IRB Barcelona Charles River Labs Hubrecht Institute

'In the future, people will be able to look for their genes of interest and mine it for new hypotheses', Single Cell Discoveries CEO Mauro Muraro predicts. persist-seq.org/news/building-…

"IRB Barcelona has developed human-like “state of the art” experimental models of advanced colorectal cancer that aid to model therapeutic resistance", The BATLLE Lab head Eduard Batlle explains. How are these models used in PERSIST-SEQ's research? Read more: persist-seq.org/news/modelling…

Prof. Rene Bernards’ lab at The Netherlands Cancer Institute is a crucial partner in PERSIST-SEQ with its integral role to find vulnerabilities of drug tolerant persister cells in #cancer. Learn more about this work in our project here: persist-seq.org/news/applying-… Oncode Institute AstraZeneca

What were the highlights of the first years of Oncode for our Investigators? Alexander van Oudenaarden talks about the founding of PERSIST-SEQ: a public-private consortium that aims to capture tumour drug persistence. In this project, collaboration is key 👉 youtube.com/watch?v=xW-5jM…

Advanced preclinical models are needed to improve our understanding of #tumour resistance to drug treatments. PERSIST-SEQ esearchers will develop models enriched in persistent tumour cells to facilitate their analysis with PERSIST-SEQ sequencing workflows persist-seq.org/news/novel-mod…

Last week, the second PERSIST-SEQ consortium meeting took place as a hybrid event – organised in Cambridge, The United Kingdom, with the option for project members to join online. Find out more about the sessions and speakers: persist-seq.org/news/second-pe… Oncode Institute AstraZeneca

Despite advances in the field of #invitro modelling, it remains difficult to recreate artificial models which reproduce the complex and heterogeneous microenvironment of actual #tumours. Learn how PERSIST-SEQ scientists at Transgene address this: persist-seq.org/news/developin…

Scientists at PERSIST-SEQ's partner Vall d’Hebron Institute of Oncology (VHIO) - a research centre for personalized medicine in #oncology, study the mechanisms that allow #tumours to resist effective treatments and to progress to advanced stages where patients’ lives are at risk. Learn more: persist-seq.org/news/multi-omi…

In PERSIST-SEQ, Bayer AG provides support with consortium management, contributes to the work on experimental #tumour models, and leverages its #IT infrastructure for the planned analyses within the #bioinformatics workstream in PERSIST-SEQ: persist-seq.org/news/bayer-con…

Happy new year! Check out the first edition of our e-newsletter with updates on our project 👉persist-seq.org/news/welcome-f… We look forward to continuing our work on study technical plans and sample submissions, and initiating data analysis in 2023! Oncode Institute AstraZeneca

Tomorrow is #WorldCancerDay2023 PERSIST-SEQ's goal is to improve the understanding of therapeutic resistance in #cancer and create effective strategies to improve cancer treatment and prevent drug resistance. Subscribe to our newsletter for regular updates persist-seq.org

PERSIST-SEQ's partner Xenopat contributes its collection of xenografts to the consortium for the study of cancer resistance mechanisms to standard chemotherapy treatments. Learn more about Xenopat's role in and contributions to our project here: persist-seq.org/news/potential…

In PERSIST-SEQ, Charles River Labs brings it longstanding management expertise, and its industry know-how and standards regarding #GDPR, animal welfare and patient informed consent, especially in the context of generation and usage of patient derived #xenografts: persist-seq.org/news/charles-r…

Researchers at PERSIST-SEQ partner IFOM recently found previously unknown vulnerabilities of #colorectalcancer cells that survived lethal doses of targeted therapies which could be exploited therapeutically. Learn about IFOM’s role in PERSIST-SEQ: persist-seq.org/news/single-ce…

Check out our second newsletter in which we share our progress to date and future plans! So far, we've sequenced 86,518 persister cells, with lung cancer as the predominant tumour type. Find out more about our work progress: persist-seq.org/news/welcome-s… AstraZeneca Oncode Institute